MaxCyte, Inc. (MXCT) stock

MXCTNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3065% below fair value

$1.10−0.03 (-2.65%)

Close on Nov 11, 2026Market cap $113.53MP/E –Yield –

MaxCyte ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

MaxCyte's ebitda for the twelve months ending Sep 30, 2026 was -$29.74M. For fiscal 2025 it was -$47.56M. The highest annual figure on record is -$10.01M in fiscal 2020.

Annual ebitda

Period	Period end	Value	Change
FY2025	Dec 31, 2025	-$47.56M	–
FY2024	Dec 31, 2024	-$46.88M	–
FY2023	Dec 31, 2023	-$44.13M	–
FY2022	Dec 31, 2022	-$24.66M	–
FY2021	Dec 31, 2021	-$16.76M	–
FY2020	Dec 31, 2020	-$10.01M	–
FY2019	Dec 31, 2019	-$11.81M	–

Quarterly ebitda

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2026	Sep 30, 2026	-$5.17M	–
Q2 FY2026	Jun 30, 2026	-$9.28M	–
Q1 FY2026	Mar 31, 2026	-$5.14M	–
Q4 FY2025	Dec 31, 2025	-$10.15M	–
Q3 FY2025	Sep 30, 2025	-$13.11M	–
Q2 FY2025	Jun 30, 2025	-$13.15M	–
Q1 FY2025	Mar 31, 2025	-$11.20M	–
Q4 FY2024	Dec 31, 2024	-$11.84M	–
Q3 FY2024	Sep 30, 2024	-$13.03M	–
Q2 FY2024	Jun 30, 2024	-$10.93M	–
Q1 FY2024	Mar 31, 2024	-$11.16M	–
Q4 FY2023	Dec 31, 2023	-$6.99M	–
Q3 FY2023	Sep 30, 2023	-$12.87M	–
Q2 FY2023	Jun 30, 2023	-$12.05M	–
Q1 FY2023	Mar 31, 2023	-$12.22M	–
Q4 FY2022	Dec 31, 2022	-$5.83M	–
Q3 FY2022	Sep 30, 2022	-$6.97M	–
Q2 FY2022	Jun 30, 2022	-$8.19M	–
Q1 FY2022	Mar 31, 2022	-$3.67M	–
Q4 FY2021	Dec 31, 2021	-$4.54M	–
Q3 FY2021	Sep 30, 2021	-$2.08M	–
Q2 FY2021	Jun 30, 2021	-$4.09M	–
Q1 FY2021	Mar 31, 2021	-$6.06M	–
Q4 FY2020	Dec 31, 2020	-$2.10M	–
Q3 FY2020	Sep 30, 2020	-$2.55M	–
Q2 FY2020	Jun 30, 2020	-$2.59M	–